HUTCHMED (China) Limited (HCM)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$14.31+0.77%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $2.5B
- P/E (trailing)
- 143.1
- Forward P/E
- 55.2
- 52-week range
- $9.77 – $16.40
- 52-week change
- −12.40%
- EPS (trailing)
- $0.10
- Analyst rating
- 1.5 Strong buy
Fiscal year to Dec 2025
- Revenue
- $549M (−12.96%)
- Net income
- $457M
- Operating margin
- −7.1%
- Diluted EPS
- $0.52
- Free cash flow
- −$78.8M
From the company’s annual report on SEC EDGAR.
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Headquarters: Hong Kong, Hong Kong · 1,790 employees · hutch-med.com